Roche's Vabysmo sales reached 1.02 billion Swiss ... the FDA last week rejected the company’s application for a prefilled syringe version of Eylea HD. Just days before that complete response ...

Moreover, in April 2025, Regeneron's US supplementary application for Eylea HD's prefilled syringe was rejected; this packaging format is important for the product's competitiveness with Vabysmo ...

Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye disease drug Eylea, sending the company's shares tumbling 7% in premarket ...

However, the regulatory body issued a complete response letter (CRL) for the Eylea HD pre-filled syringe. The CRL was mostly issued ... under pressure for some time now due to competition from Vabysmo ...

However, the regulatory body issued a complete response letter (CRL) for the Eylea HD pre-filled syringe ... some time now due to competition from Vabysmo. We note that Vabysmo's uptake has ...

Vabysmo keeps expanding market share in all ... growth outside the US as new countries come online and as the prefilled syringe continues to enter into new markets. So overall we think it is ...

The global Injectable Drug Delivery Market, valued at US$633.7 billion in 2024, is forecasted to grow at a robust CAGR of 8.4%, reaching US$690.23 billion in 2025 and an impressive US$1,034.78 billion ...

Vabysmo continues to gain market share, achieving leadership position in neovascular age-related macular degeneration (nAMD). The product has shown strong uptake of its pre-filled syringe formulation, ...

With these label enhancements and anticipated approval of the prefilled syringe, we expect to see ... it could go to support Vabysmo, it could go to support Pavblu, it could go to support EYLEA ...